Safety and tolerability of ataluren in a phase 3 study of patients with nonsense mutation duchenne muscular dystrophy

The requested reference [3c1707d671559dfddf9ed71be64c13312435c3fc] no longer exists in our database. It has been replaced by the current reference: [fde269c4f9d23309a7c8661b20db7ff5e6fcaa80]

Authors
Category Primary study
JournalNeurology
Year 2016
This article has no abstract
Epistemonikos ID: 54fc33de23e3f02b50640a948074a2f8bce0f0df
First added on: Feb 07, 2025